Ocrelizumab Secures Expanded Approval for Pediatric Multiple Sclerosis Roche has received authorization to expand the use of ocrelizumab for children and adolescents aged 12 and older with relapsing-remitting multiple sclerosis. Patients must weigh at least 40 kilograms to qualify. Pediatric MS is rare but highly inflammatory and can severely affect cognitive and social development. This regulatory green light relies on the Phase III OPERETTA 2 trial, which proved the monoclo

Winrevair (sotatercept) has been approved for treating adults with pulmonary arterial hypertension (PAH), classified under World Health...

16, April 2024 Rybrevant is approved in Brazil for locally advanced or metastatic non-small cell lung cancer Rybrevant (amivantamab) is...

Brazilian Health Ministry Decided to Use Unspent R$17 billion ($3.4 billion) Which was Not utilized During COVID-19 Period Approximately...

January 09, 2024 Recombinant COVID-19 vaccine is approved by ANVISA in Brazil to prevent COVID-19 infection Designed for the immunization...

Ondexxya is prescribed for patients undergoing treatment with FXa inhibitors such as apixaban or rivaroxaban when there is an urgent need...